To study the efficacy and safety of recombinant human prourokinase in the treatment of acute pulmonary embolism (APE).
A total of 78 cases of APE patients from September 2015 to August 2016 admitted were divided into observation group and control group according to the order of admission. The observation group was received recombinant human prourokinase, and the control group was given urokinase for treatment. The total effective rates of the two groups were calculated, and the blood gas, blood pressure, coagulation and the fibrinolysis related indexes of two groups before and after treatment were compared. The incidences of adverse drug reactions in two groups were observed.
After treatment, the total effective rate of the observation group was higher than that of the control group (89.74% vs 61.54%, P<0.05). Compared with before treatment, the blood gas, blood pressure, coagulation and the fibrinolysis related indexes of two groups after treatment were improved (P<0.01). The arterial oxygen pressure and systolic blood pressure in observation group were higher than those in control group [(88.96±8.43) mmHg, (132.98±14.65) mmHg vs (78.98±7.87) mmHg, (122.97±12.89) mmHg](P<0.05, P<0.01), and the pulmonary artery systolic pressure was lower than that of control group [(32.98±3.84) mmHg vs (45.98±4.87)mmHg](P<0.01). The tissue type plasminogen activator, plasminogen activator inhibitor-1, coagulation regulator protein, protein C, protein S, plasma D-dimer (DD) in observation group were lower than those in control group [(6.04±0.61) μg/L, (48.21±4.25) μg/L, (3.51±0.32) μg/L, (2.14±0.26) mg/L (13.56±1.46) mg/L, and (0.72±0.04) mg/L vs (9.87±0.93) μg/L, (54.32±5.11) μg/L, (5.15±0.53) μg/L, (3.24±0.37) mg/L, (19.58±1.94) mg/L, and (1.03±0.09) mg/L](P<0.01). The adverse drug reaction rate in observation group was lower than that in control group (7.69% vs 35.90%, P<0.05).
Recombinant human prourokinase is effective in the treatment of APE. It can effectively improve blood gas, blood pressure, coagulation and the fibrinolysis related indexes, and has less adverse drug reactions such as bleeding.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |